Check out our most popular compounded medications! Get Started
Theophylline 75 mg Slow Release (ME4M) Oral Capsules are specially formulated to provide a controlled and prolonged release of the active ingredient, theophylline. Utilizing Methocel E4M, a controlled-release polymer, these capsules ensure a gradual release of medication, offering sustained therapeutic effects and reducing the frequency of dosing.
By improving patient compliance through reduced dosing frequency, these capsules support better management of these chronic respiratory disease states.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Theophylline 75 mg Slow Release (ME4M) Oral Capsules are designed to provide a controlled and prolonged release of theophylline, a bronchodilator commonly used in the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The use of Methocel E4M in the formulation allows for a sustained therapeutic effect, reducing the frequency of dosing and potentially improving patient compliance. However, it is crucial to be aware of potential drug interactions that may affect the efficacy and safety of theophylline therapy.
Theophylline is metabolized primarily by the cytochrome P450 enzyme system, particularly CYP1A2, and to a lesser extent by CYP2E1 and CYP3A4. Consequently, drugs that induce or inhibit these enzymes can significantly alter theophylline levels. For instance, CYP1A2 inhibitors such as ciprofloxacin, fluvoxamine, and oral contraceptives can increase theophylline plasma concentrations, potentially leading to toxicity. Conversely, CYP1A2 inducers like rifampin, phenytoin, and carbamazepine may decrease theophylline levels, reducing its therapeutic efficacy.
Additionally, theophylline has a narrow therapeutic index, meaning that small changes in drug concentration can lead to subtherapeutic effects or toxicity. Symptoms of theophylline toxicity include nausea, vomiting, diarrhea, insomnia, and in severe cases, seizures and cardiac arrhythmias. Therefore, it is essential to monitor theophylline levels when initiating or discontinuing medications that may interact with it.
Other drugs that may interact with theophylline include beta-blockers, which can antagonize its bronchodilatory effects, and certain antibiotics like erythromycin and clarithromycin, which can increase theophylline levels. Furthermore, lifestyle factors such as smoking can induce CYP1A2, leading to decreased theophylline levels, while cessation of smoking can increase the risk of toxicity due to elevated theophylline concentrations.
Patients should be advised to inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to assess potential interactions. Regular monitoring of theophylline levels and clinical response is recommended, especially when there are changes in medication regimens or lifestyle factors that may affect drug metabolism.
For prescribers, it is important to consider these interactions when prescribing theophylline and to adjust dosages accordingly. Close communication with patients regarding the importance of adherence to prescribed dosing schedules and monitoring for signs of toxicity or subtherapeutic effects is crucial for optimizing treatment outcomes.
If you have any questions or require further information regarding theophylline interactions or this specific formulation, please reach out to us at Bayview Pharmacy. We are here to assist both patients and healthcare providers in ensuring safe and appropriate use of theophylline therapy.
Theophylline 75 mg Slow Release (ME4M) Oral Capsules are designed to provide a controlled and sustained release of the active ingredient, theophylline, which is commonly used in the management of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The formulation utilizes Methocel E4M, a type of hydroxypropyl methylcellulose (HPMC) polymer, which is specifically engineered to control the release rate of theophylline over an extended period. This slow-release mechanism ensures that the medication is gradually absorbed into the bloodstream, maintaining therapeutic drug levels for a longer duration compared to immediate-release formulations.
The use of Methocel E4M in the capsule formulation is crucial for achieving the desired pharmacokinetic profile. As the capsule dissolves in the gastrointestinal tract, the Methocel E4M polymer forms a gel-like matrix that encapsulates the theophylline particles. This matrix acts as a barrier, regulating the rate at which the drug is released. The polymer's properties allow for a consistent and predictable release pattern, minimizing fluctuations in drug concentration and reducing the risk of side effects associated with peak plasma levels.
For patients, the benefits of this slow-release formulation are significant. By maintaining steady drug levels, theophylline 75 mg Slow Release (ME4M) Oral Capsules help to provide continuous relief from symptoms such as wheezing, shortness of breath, and chest tightness. This can lead to improved overall respiratory function and a better quality of life. Additionally, the reduced dosing frequency associated with slow-release formulations enhances patient compliance, as it simplifies the medication regimen and reduces the burden of frequent dosing.
For prescribers, theophylline 75 mg Slow Release (ME4M) Oral Capsules offer a reliable option for managing chronic respiratory conditions. The controlled-release profile allows for more consistent therapeutic outcomes and can be particularly beneficial for patients who experience difficulty adhering to multiple daily doses. Furthermore, the predictable release pattern of theophylline can aid in minimizing the risk of adverse effects, such as nausea, insomnia, and palpitations, which are often associated with fluctuating drug levels.
Overall, theophylline 75 mg Slow Release (ME4M) Oral Capsules represent an advanced formulation designed to optimize the therapeutic management of asthma and COPD. By leveraging the controlled-release properties of Methocel E4M, this formulation provides sustained drug delivery, improved patient adherence, and enhanced clinical outcomes. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy.
Theophylline 75 mg Slow Release (ME4M) Oral Capsules, formulated with Methocel E4M, are primarily used for the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, beyond these primary indications, theophylline has been explored for other potential therapeutic uses due to its pharmacological properties. One such use is in the management of apnea of prematurity in neonates. Theophylline acts as a central nervous system stimulant and can help reduce the frequency of apnea episodes by stimulating the respiratory center in the brain, thereby improving breathing patterns in premature infants. This application requires careful monitoring and dosing adjustments due to the narrow therapeutic index of theophylline and the unique pharmacokinetics in neonates.
Additionally, theophylline has been investigated for its potential benefits in treating certain cardiovascular conditions. Its ability to act as a bronchodilator and improve respiratory function can indirectly benefit patients with heart failure by enhancing oxygenation and reducing pulmonary congestion. Furthermore, theophylline's mild diuretic effect can aid in fluid management in these patients. However, these uses are less common and should be considered only when standard treatments are inadequate, and under strict medical supervision due to the risk of adverse effects and drug interactions.
In some cases, theophylline has been used off-label for its anti-inflammatory properties, which may be beneficial in conditions characterized by chronic inflammation. Research is ongoing to better understand the scope of its anti-inflammatory effects and potential applications in diseases such as inflammatory bowel disease or certain types of arthritis. However, these uses are experimental and should be approached with caution, ensuring that the benefits outweigh the risks for each individual patient.
For both patients and prescribers considering theophylline for these alternative uses, it is crucial to conduct a thorough assessment of the patient's overall health status, concurrent medications, and potential for drug interactions. Regular monitoring of theophylline serum levels is essential to avoid toxicity, given its narrow therapeutic window. If you have any questions or need further information about theophylline 75 mg Slow Release (ME4M) Oral Capsules and their potential uses, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with personalized advice and support.
Theophylline 75 mg Slow Release (ME4M) Oral Capsules are used to manage and treat symptoms of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) by relaxing the muscles in the lungs and chest, making it easier to breathe.
The capsules are formulated with Methocel E4M, a controlled-release polymer that gradually releases the active ingredient, Theophylline, over an extended period. This ensures sustained therapeutic effects and reduces the frequency of dosing.
Slow-release formulations offer several benefits, including prolonged therapeutic effects, reduced dosing frequency, improved patient compliance, and a more consistent delivery of medication, which can help maintain stable blood levels of the drug.
The dosing frequency will depend on your specific medical condition and response to treatment. It is important to follow your healthcare provider's instructions regarding how often to take the medication.
Yes, Theophylline 75 mg Slow Release (ME4M) Oral Capsules can be taken with or without food. However, it is advisable to take them consistently in the same manner to maintain stable drug levels in your body.
Some common side effects may include nausea, headache, insomnia, and irritability. If you experience severe side effects or signs of an allergic reaction, contact your healthcare provider immediately.
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.
No, you should not crush or chew the capsules as this can interfere with the slow-release mechanism and lead to a rapid release of the medication, increasing the risk of side effects.
If you are pregnant or planning to become pregnant, consult your healthcare provider before using this medication to discuss potential risks and benefits.
Store the capsules at room temperature, away from moisture and heat. Keep them out of reach of children and pets.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
